ARDX
Price
$5.77
Change
+$0.23 (+4.15%)
Updated
Dec 3 closing price
Capitalization
1.4B
97 days until earnings call
Intraday BUY SELL Signals
FOLD
Price
$9.78
Change
+$0.05 (+0.51%)
Updated
Dec 3 closing price
Capitalization
3.02B
77 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARDX vs FOLD

Header iconARDX vs FOLD Comparison
Open Charts ARDX vs FOLDBanner chart's image
Ardelyx
Price$5.77
Change+$0.23 (+4.15%)
Volume$2.58M
Capitalization1.4B
Amicus Therapeutics
Price$9.78
Change+$0.05 (+0.51%)
Volume$2.92M
Capitalization3.02B
ARDX vs FOLD Comparison Chart in %
View a ticker or compare two or three
VS
ARDX vs. FOLD commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARDX is a StrongBuy and FOLD is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (ARDX: $5.54 vs. FOLD: $9.73)
Brand notoriety: ARDX and FOLD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARDX: 30% vs. FOLD: 33%
Market capitalization -- ARDX: $1.4B vs. FOLD: $3.02B
ARDX [@Biotechnology] is valued at $1.4B. FOLD’s [@Biotechnology] market capitalization is $3.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARDX’s FA Score shows that 0 FA rating(s) are green whileFOLD’s FA Score has 0 green FA rating(s).

  • ARDX’s FA Score: 0 green, 5 red.
  • FOLD’s FA Score: 0 green, 5 red.
According to our system of comparison, ARDX is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARDX’s TA Score shows that 5 TA indicator(s) are bullish while FOLD’s TA Score has 2 bullish TA indicator(s).

  • ARDX’s TA Score: 5 bullish, 5 bearish.
  • FOLD’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, ARDX is a better buy in the short-term than FOLD.

Price Growth

ARDX (@Biotechnology) experienced а -3.15% price change this week, while FOLD (@Biotechnology) price change was -1.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

ARDX is expected to report earnings on Mar 11, 2026.

FOLD is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($3.02B) has a higher market cap than ARDX($1.4B). ARDX YTD gains are higher at: 9.270 vs. FOLD (3.291). FOLD has higher annual earnings (EBITDA): 33.1M vs. ARDX (-29.19M). ARDX (238M) and FOLD (231M) have equal amount of cash in the bank . ARDX has less debt than FOLD: ARDX (207M) vs FOLD (443M). FOLD has higher revenues than ARDX: FOLD (571M) vs ARDX (386M).
ARDXFOLDARDX / FOLD
Capitalization1.4B3.02B46%
EBITDA-29.19M33.1M-88%
Gain YTD9.2703.291282%
P/E RatioN/AN/A-
Revenue386M571M68%
Total Cash238M231M103%
Total Debt207M443M47%
FUNDAMENTALS RATINGS
ARDX vs FOLD: Fundamental Ratings
ARDX
FOLD
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
92100
SMR RATING
1..100
9695
PRICE GROWTH RATING
1..100
4340
P/E GROWTH RATING
1..100
36100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FOLD's Valuation (56) in the Biotechnology industry is somewhat better than the same rating for ARDX (100). This means that FOLD’s stock grew somewhat faster than ARDX’s over the last 12 months.

ARDX's Profit vs Risk Rating (92) in the Biotechnology industry is in the same range as FOLD (100). This means that ARDX’s stock grew similarly to FOLD’s over the last 12 months.

FOLD's SMR Rating (95) in the Biotechnology industry is in the same range as ARDX (96). This means that FOLD’s stock grew similarly to ARDX’s over the last 12 months.

FOLD's Price Growth Rating (40) in the Biotechnology industry is in the same range as ARDX (43). This means that FOLD’s stock grew similarly to ARDX’s over the last 12 months.

ARDX's P/E Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for FOLD (100). This means that ARDX’s stock grew somewhat faster than FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARDXFOLD
RSI
ODDS (%)
Bearish Trend 7 days ago
85%
Bearish Trend 7 days ago
75%
Stochastic
ODDS (%)
Bullish Trend 7 days ago
90%
Bearish Trend 7 days ago
81%
Momentum
ODDS (%)
Bearish Trend 7 days ago
82%
N/A
MACD
ODDS (%)
Bearish Trend 7 days ago
86%
N/A
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
84%
Bullish Trend 7 days ago
71%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
83%
Bullish Trend 7 days ago
74%
Advances
ODDS (%)
Bullish Trend 9 days ago
87%
Bullish Trend 11 days ago
69%
Declines
ODDS (%)
Bearish Trend 14 days ago
81%
Bearish Trend 28 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 7 days ago
86%
Aroon
ODDS (%)
Bullish Trend 7 days ago
84%
Bullish Trend 7 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
ARDX
Daily Signal:
Gain/Loss:
FOLD
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRRFX17.95N/A
N/A
BlackRock Mid-Cap Value R
HBGIX22.72N/A
N/A
Hartford Disciplined Equity HLS IB
RYTHX232.37N/A
N/A
Rydex Technology A
MISGX12.84N/A
N/A
Meridian Small Cap Growth Investor
JFRDX59.86N/A
N/A
Janus Henderson Forty D

ARDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARDX
1D Price
Change %
ARDX100%
-0.89%
VCYT - ARDX
45%
Loosely correlated
-0.43%
PCVX - ARDX
35%
Loosely correlated
-1.80%
FOLD - ARDX
35%
Loosely correlated
-0.71%
RNAC - ARDX
35%
Loosely correlated
-7.95%
CLRB - ARDX
31%
Poorly correlated
-2.95%
More

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with RARE. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then RARE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
-0.71%
RARE - FOLD
45%
Loosely correlated
+0.28%
XNCR - FOLD
45%
Loosely correlated
-3.15%
BMRN - FOLD
44%
Loosely correlated
-2.07%
KURA - FOLD
44%
Loosely correlated
-2.53%
CLDX - FOLD
44%
Loosely correlated
+2.85%
More